- Company List - C
- CTNM
Insider Trading activities at Contineum Therapeutics, Inc. (CTNM)
Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Contineum Therapeutics, Inc. (CTNM)
since 2024 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Contineum Therapeutics, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1855175.
Total stock buying since 2024: $0.
Total stock sales since 2024: $748,344.
Total stock option exercises since 2024: $79,835.
Table 1. Yearly summary of insider stock purchases, sales, and option exercises
at Contineum Therapeutics, Inc. (CTNM).
|
Insider Buying |
Insider Sales |
Option Exercises |
| Year |
Shares | Value |
Shares | Value |
Shares | Value |
| 2026 | 0 | $0 | 35,856 | $534,154 | 23,346 | $50,658 |
| 2025 | 0 | $0 | 7,781 | $94,566 | 3,611 | $16,249 |
| 2024 | 0 | $0 | 7,200 | $119,624 | 12,800 | $12,928 |
Table 2. Monthly summary of insider trading at Contineum Therapeutics, Inc. (CTNM).
| Trading Period |
Insider Buying |
Insider Sales |
Option Exercises |
| year-month |
Shares | Value |
Shares | Value |
Shares | Value |
| 2026-03 | 0 | $0 | 7,781 | $116,802 | 3,611 | $16,249 |
| 2026-02 | 0 | $0 | 20,294 | $320,988 | 16,124 | $18,160 |
| 2026-01 | 0 | $0 | 7,781 | $96,364 | 3,611 | $16,249 |
| 2025-12 | 0 | $0 | 7,781 | $94,566 | 3,611 | $16,249 |
| 2024-11 | 0 | $0 | 7,200 | $119,624 | 0 | $0 |
| 2024-08 | 0 | $0 | 0 | $0 | 12,800 | $12,928 |
Table 3. Detailed insider trading at Contineum Therapeutics, Inc. (CTNM)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2026-03-02 | Watkins Tim (CMO & Head of Development) | Sale | 3,611 | 15.02 | 54,219 |
| 2026-03-02 | Watkins Tim (CMO & Head of Development) | Option Ex | 3,611 | 4.50 | 16,249 |
| 2026-03-02 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 4,170 | 15.01 | 62,583 |
| 2026-02-25 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 3,824 | 16.01 | 61,229 |
| 2026-02-25 | Lorrain Daniel S. (Chief Scientific Officer) | Option Ex | 3,824 | 1.01 | 3,862 |
| 2026-02-25 | Stengone Carmine N. (CEO and President) | Sale | 2,700 | 16.02 | 43,243 |
| 2026-02-25 | Stengone Carmine N. (CEO and President) | Option Ex | 2,700 | 1.26 | 3,402 |
| 2026-02-24 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 4,300 | 16.03 | 68,937 |
| 2026-02-24 | Lorrain Daniel S. (Chief Scientific Officer) | Option Ex | 4,300 | 1.01 | 4,343 |
| 2026-02-24 | Stengone Carmine N. (CEO and President) | Sale | 4,400 | 16.02 | 70,488 |
| 2026-02-24 | Stengone Carmine N. (CEO and President) | Option Ex | 4,400 | 1.26 | 5,544 |
| 2026-02-19 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 100 | 16.00 | 1,600 |
| 2026-02-19 | Lorrain Daniel S. (Chief Scientific Officer) | Option Ex | 100 | 1.01 | 101 |
| 2026-02-11 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 400 | 16.00 | 6,400 |
| 2026-02-11 | Lorrain Daniel S. (Chief Scientific Officer) | Option Ex | 400 | 1.01 | 404 |
| 2026-02-11 | Stengone Carmine N. (CEO and President) | Sale | 400 | 16.00 | 6,400 |
| 2026-02-11 | Stengone Carmine N. (CEO and President) | Option Ex | 400 | 1.26 | 504 |
| 2026-02-03 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 4,170 | 15.03 | 62,691 |
| 2026-01-28 | Watkins Tim (CMO & Head of Development) | Sale | 3,611 | 14.29 | 51,583 |
| 2026-01-28 | Watkins Tim (CMO & Head of Development) | Option Ex | 3,611 | 4.50 | 16,249 |
| 2026-01-05 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 4,170 | 10.74 | 44,781 |
| 2025-12-29 | Watkins Tim (CMO & Head of Development) | Sale | 3,611 | 12.06 | 43,559 |
| 2025-12-29 | Watkins Tim (CMO & Head of Development) | Option Ex | 3,611 | 4.50 | 16,249 |
| 2025-12-23 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 4,170 | 12.23 | 51,007 |
| 2024-11-25 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 1,010 | 16.02 | 16,177 |
| 2024-11-18 | Lorrain Daniel S. (Chief Scientific Officer) | Sale | 6,190 | 16.71 | 103,447 |
| 2024-08-13 | Huhn Stephen L. (CMO & Sr VP, Clinical Dev.) | Option Ex | 12,800 | 1.01 | 12,928 |
Insider trading activities including stock purchases, stock sales, and option exercises
of CTNM listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Contineum Therapeutics, Inc. (symbol CTNM,
CIK number 1855175) see
the Securities and Exchange Commission (SEC) website.